Radioembolization
8
5
6
2
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 8 trials
100.0%
+13.5% vs benchmark
0%
0 trials in Phase 3/4
0%
0 of 2 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (8)
Scout Dose of Resin Microspheres
qDSA Blood Flow Measurement in Patients Undergoing TAE of the Liver
A Prospective Observational Study on Efficacy of TARE for Early Stage HCC
Ablative Radioembolization of Renal Cell Carcinoma Trial
Building Evidence for Ablative Internal Radiation Therapy in Localized HCC Beyond the Up-To-7 Criteria
Multi-modal Characterisation of Hepatocellular Carcinoma (HCC) Treated With Targeted Radionuclide Therapy (TRT): Prospective Interventional Multicentre National Cohort
Assessment of Hypoxia Before Radioembolization Treatment With 18F-FMISO PET
Radioembolization With Yittrium-90 for Intermediate and Advanced Hepatocellular Carcinoma